このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Duopharma Biotech Berhad 将来の成長

Future 基準チェック /46

Duopharma Biotech Berhad利益と収益がそれぞれ年間24.8%と8.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に11.8% 26.2%なると予測されています。

主要情報

24.9%

収益成長率

25.9%

EPS成長率

Pharmaceuticals 収益成長	16.6%
収益成長率	8.3%
将来の株主資本利益率	11.9%
アナリストカバレッジ	Low
最終更新日	21 Jun 2024

今後の成長に関する最新情報

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12

業績と収益の成長予測

KLSE:DPHARMA - アナリストの将来予測と過去の財務データ ( )MYR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	880	99	88	123	4
12/31/2025	826	91	72	112	5
12/31/2024	768	76	79	122	5
3/31/2024	697	45	40	70	N/A
12/31/2023	705	53	9	49	N/A
9/30/2023	689	61	-10	40	N/A
6/30/2023	697	69	-17	35	N/A
3/31/2023	711	72	-32	29	N/A
12/31/2022	697	70	-1	70	N/A
9/30/2022	690	69	21	84	N/A
6/30/2022	685	69	-33	48	N/A
3/31/2022	659	68	-49	63	N/A
12/31/2021	639	66	-72	43	N/A
9/30/2021	628	66	-117	7	N/A
6/30/2021	590	63	-51	58	N/A
3/31/2021	578	63	-21	59	N/A
12/31/2020	570	59	6	71	N/A
9/30/2020	574	54	45	110	N/A
6/30/2020	583	55	37	97	N/A
3/31/2020	585	54	35	96	N/A
12/31/2019	576	55	6	67	N/A
9/30/2019	554	58	-9	63	N/A
6/30/2019	537	55	-5	87	N/A
3/31/2019	516	51	-7	78	N/A
12/31/2018	499	48	-20	72	N/A
9/30/2018	495	45	-33	51	N/A
6/30/2018	485	44	-31	49	N/A
3/31/2018	478	44	-44	34	N/A
12/31/2017	468	42	N/A	56	N/A
9/30/2017	430	39	N/A	38	N/A
6/30/2017	395	34	N/A	20	N/A
3/31/2017	357	29	N/A	25	N/A
12/31/2016	313	27	N/A	33	N/A
9/30/2016	327	31	N/A	50	N/A
6/30/2016	326	33	N/A	56	N/A
3/31/2016	304	35	N/A	-60	N/A
12/31/2015	270	36	N/A	-51	N/A
9/30/2015	232	34	N/A	-53	N/A
6/30/2015	198	34	N/A	-59	N/A
3/31/2015	182	36	N/A	49	N/A
12/31/2014	177	35	N/A	36	N/A
9/30/2014	172	33	N/A	27	N/A
6/30/2014	168	31	N/A	28	N/A
3/31/2014	165	34	N/A	39	N/A
12/31/2013	162	32	N/A	40	N/A
9/30/2013	152	30	N/A	44	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DPHARMAの予測収益成長率 (年間24.8% ) は貯蓄率 ( 3.6% ) を上回っています。

収益対市場: DPHARMAの収益 ( 24.8% ) はMY市場 ( 12.4% ) よりも速いペースで成長すると予測されています。

高成長収益: DPHARMAの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: DPHARMAの収益 ( 8.5% ) MY市場 ( 6.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: DPHARMAの収益 ( 8.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DPHARMAの自己資本利益率は、3年後には低くなると予測されています ( 11.8 %)。

Duopharma Biotech Berhad 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 11%

Price target decreased by 8.3% to RM1.63

Price target increased to RM1.81

Price target decreased to RM1.97

Price target decreased to RM3.10

Price target raised to RM2.45

Recent updates

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Consensus EPS estimates fall by 11%

Upcoming dividend of RM0.018 per share

Full year 2023 earnings released: EPS: RM0.055 (vs RM0.074 in FY 2022)

Now 20% undervalued

Third quarter 2023 earnings released: EPS: RM0.009 (vs RM0.017 in 3Q 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Price target decreased by 8.3% to RM1.63

Second quarter 2023 earnings released: EPS: RM0.013 (vs RM0.017 in 2Q 2022)

Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Full year 2022 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Upcoming dividend of RM0.018 per share at 1.5% yield

Full year 2022 earnings released: EPS: RM0.074 (vs RM0.071 in FY 2021)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target increased to RM1.81

Insufficient new directors

Third quarter 2022 earnings released: EPS: RM0.017 (vs RM0.018 in 3Q 2021)

Insufficient new directors

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Insufficient new directors

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Second quarter 2022 earnings released: EPS: RM0.017 (vs RM0.016 in 2Q 2021)

Duopharma Biotech Berhad Announces an Interim Dividend, Payable on 14 September 2022

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad, Annual General Meeting, Jun 21, 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of RM0.018 per share

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Full year 2021 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Declares Second Interim Dividend in Respect of the Financial Year Ended 31 December 2021

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Price target decreased to RM1.97

Third quarter 2021 earnings released: EPS RM0.018 (vs RM0.015 in 3Q 2020)

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Second quarter 2021 earnings released: EPS RM0.022 (vs RM0.022 in 2Q 2020)

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Upcoming dividend of RM0.06 per share

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Price target decreased to RM3.10

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment deteriorated over the past week

New 90-day low: RM3.03

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Revenue behind estimates

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Price target raised to RM2.45

Government of Malaysia, Biocon Sdn. Bhd. and Duopharma Biotech Berhad Extends the Contract Period Under the Agreement One Year Effective from 2 December 2020 Until 1 December 2021

Duopharma Biotech Berhad Announces Temporary Closure of Registered Office

First half earnings released

New 90-day high - RM3.29

業績と収益の成長予測